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Lack of antiretroviral therapy is associated with
higher risk of neurosyphilis among HIV-infected
patients who remain serofast after therapy for
early syphilis
Maciej Pastuszczak, MD, PhDa,
∗
, Marek Sitko, MDb, Monika Bociaga-Jasik, MD, PhDb,
Jakub Kucharz, MD, PhDc, Anna Wojas-Pelc, MD, PhDa
Abstract
Resolution of clinical symptoms and at least 4-fold decline in nontreponemal antibody titers after treatment of syphilis is regarded as
“proof of cure.” However, a substantial proportion of patients demonstrates <4-fold reduction of titers after recommended therapy
(serofast state). It remains unclear whether the serofast state is indicative of persistence of bacteria or only a residual immune
response.
The aim of the present study was to determine the association between the serofast state and the risk of neurosyphilis in human
immunodeficiency virus (HIV)-infected individuals and to identify potential predictors of neurosyphilis.
Thirty-three patients with early syphilis and HIV co-infection were included. One year after the recommended treatment of syphilis,
all patients who did not achieve proper serologic response underwent lumbar puncture and cerebrospinal fluid (CSF) examination.
Twelve months after completing therapy for syphilis, the proportion of patients with serofast state after syphilis therapy was 36.4%
(n=12). Among them, 5 (41.7%) had neurosyphilis. Individuals who remained serofast and had neurosyphilis (n=5) when compared
to those without neurosyphilis (n=7) were characterized by significantly lower CD4+ cell count and higher HIV RNA levels (P< .05).
Moreover, a significantly higher proportion of patients with neurosyphilis was not receiving antiretroviral therapy (ART). The nonreceipt
of ART independently increased the risk of neurosyphilis in the analyzed group of serofast HIV-infected patients (odds ratio=4.5;
95% confidence interval 1.5–13.59, P= .003).
Patients co-infected with HIV require careful serologic and clinical follow-up after therapy for syphilis. In all of the patients who do
not respond serologically after treatment for syphilis, especially in those who are not receiving ART, lumbar puncture and CSF
examination should be considered.
Abbreviations: ART = antitertroviral therapy, CDC =Centers for Disease Control and Prevention, CNS = central nervous system,
CSF = cerebrospinal fluid, HIV = human immunodeficiency virus, RPR = rapid plasma reagin assay, TPHA = Treponema pallidum
hemagglutination assay, VDRL = Venereal Disease Research Laboratory assay, WBC = white blood cell.
Keywords: antiretroviral therapy, human immunodeficiency virus, neurosyphilis, penicillin, serofast
1. Introduction
Since 2000, the overall number of cases of syphilis has increased
worldwide. Rates are highest among men, and 75% of patients
are men who have sex with men; more than a half of these
individuals are human immunodeficiency virus (HIV) infected.[1]
Neurosyphilis, which is the involvement of the central nervous
system (CNS) by Treponema pallidum subsp pallidum (an
etiologic agent of syphilis), is one of the most feared
complications of syphilis. Some recent studies demonstrated
that alteration of the immune system during HIV infection
appears to enhance the persistence of bacteria in the CNS, which
is associated with more frequent occurrence of neurosyphilis in
HIV-infected individuals.[2–4]
Parental penicillin is the therapy of choice at every stage of
syphilis, but assessment of treatment efficacy relies almost
entirely on serological tests. Appropriate serologic response in
syphilis has been defined by the Centers for Disease Control and
Prevention (CDC) as a 4-fold or greater decline in the titer of a
nontreponemal assay such as the rapid plasma reagin assay
(RPR), when occurring 6 to 12 months after initiation of
treatment.[1] However, in approximately 20% of adequately
treated patients with early syphilis, the titer in the nontreponemal
assay during follow-up testing does not meet the criteria of a
proper response and does not decrease considerably, without any
clinical evidence of treatment failure or reinfection. This
condition is referred to as “serofast state syphilis.”[5] To date,
the pathogenesis and clinical significance of the serofast state is
unknown.
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So far, only a limited number of studies have tried to find an
association between an improper serologic response after therapy
for syphilis and risk of neurosyphilis.[6–8] The results are
inconclusive, presumably due to variations in enrollment of
patients at different stages of syphilis and inconsistent definitions
of neurosyphilis and serologic nonresponse. To the best of our
knowledge, none of these studies focused on HIV-infected
individuals who remain serofast after appropriate treatment for
syphilis.
Thus, the aim of this study was to assess the incidence of
neurosyphilis in serofast HIV-infected individuals and to
determine likely predictors of CNS involvement.
2. Methods
2.1. Characteristics of the patients and study design
TheHIV-infected patients with secondary and early latent syphilis
(n=33) during the 1st episode of disease were enrolled at the
DepartmentofDermatologyof the JagiellonianUniversityMedical
College (Krakow, Poland) between 2016 and 2018. Study subjects
were not treated with antibiotics or immunosuppressive agents
during the preceding 6 months. Patients with other chronic
inflammatory disorders (e.g., autoimmunity) were also excluded.
At the time of enrollment, all patients were positive both for
nontreponemal and treponemal tests, and disease staging was
determined based on clinical history and physical examination
according toCDCrecommendations.[1]A certifiedneurologist also
evaluated all study participants to assess neurologic symptoms.
HIV infection was detected at enrollment, as none of the study
participantswere aware of theirHIV status. Antiretroviral therapy
(ART) was introduced in 28 of the included individuals (84.8%).
The remaining 5 refused to initiate treatment.
All patients were administered a single dose of intramuscular
benzathine penicillin (2.4 million units) as per the recommen-
dations. Patients were followed for 12 months, with assessment
of serologic (i.e., RPR blood testing) and clinical response every 3
months. Additionally, every 3 months the HIV RNA levels (viral
load [VL]) and CD4+ cell count was determined.
Serology data indicated that 12 months after completing the
therapy of syphilis, 12 out of 33 individuals did not achieve
proper serologic response, defined as ≥4-fold decline in RPR titer
when compared to the pretreatment values. In all serologically
nonresponding patients (n=12), neurologic reexamination,
lumbar puncture, and cerebrospinal fluid (CSF) sampling were
performed. CSF samples were sent for routine examination (i.e.,
white blood cell [WBC] count, protein, and glucose concentra-
tion) and serology testing (i.e., Venereal Disease Research
Laboratory [VDRL], Treponema pallidum hemagglutination
assay [TPHA]).
Neurosyphilis was defined as reactive CSF-VDRL or elevated
CSF-WBC (i.e., ≥20cells/mL) and elevated CSF protein concen-
tration (i.e., ≥45mg/dL) according to the CDC criteria for HIV-
infected individuals. The patients (n=12) were classified as:
neurosyphilis group (n=5) and no-neurosyphilis group (n=7).
The study was approved by the Jagiellonian University
Bioethics Committee (approval number KBET/164/B) and
written informed consent was obtained from all participants.
2.2. Statistical analysis
Statistical analysis was carried out using STATISTICAL 7.1 PL
software (TIBCO Software Inc, Palo Alto, CA). If not stated
otherwise, data were expressed as median and minimum–
maximum values. Continuous variables were compared with
the Mann–Whitney U test. The Chi-squared test or the Fisher
exact test was used for the dichotomous variables. To identify
independent factors, a multivariable logistic regression analysis
was used. A P-value <.05 was considered statistically significant.
3. Results
Thirty-three previously healthy male patients aged 18 to 52 years
were enrolled in this study. The patients were in their 1st episode
of early syphilis, staged as secondary syphilis (42.4%) or early
latent syphilis (57.6%), and concomitant HIV infection was
diagnosed. At the time of enrollment, the mean CD4+ count and
HIV load were as follows: 579cells/mL (min–max: 205–1294)
and 57,300copies/mL (min–max: 224–1,370,000), respectively.
All individuals were administered intramuscular benzathine
penicillin (2.4 million units). Additionally, ARTwas offered to all
patients. However, 5 of them (15.1%) refused this treatment.
Six months after completing syphilis therapy, 18 patients
(54.5%) did not achieve at least 4-fold decline in RPR titer when
compared to the pretreatment values. This proportion decreased
to 36.4% at 12 months after therapy. At this stage, the patients
were stratified into serofast state group (n=12) and serologic-
cured group (n=21). Characteristics of both groups are shown
in Table 1. A significantly lower proportion of patients who
remained serofast 12 months after treatment of syphilis was
receiving ART (P< .05). Moreover, HIV-infected individuals
with proper serologic response after syphilis treatment were
characterized as having a significantly higher CD4+ count when
compared to those with serofast state (P= .01) (Table 1).
Twelve months after completing the syphilis treatment
neurologic examination revealed no symptoms in all serofast
Table 1
Characteristics of HIV-infected patients from serofast state group and serologic-cured group.
Serofast group (n=12) Serologic-cured group (n=21) P-value
Age (min–max), y 32 (24–52) 29 (18–38) NS
Baseline RPR (min–max) 32 (16–512) 64 (16–1048) NS
Early latent syphilis, n (%) 8 (66.7) 12 (57.1) NS
Macular exanthem on the trunk, n (%) 4 (33.3) 8 (38.1) NS
Papular exanthem on the palms and soles, n (%) 2 (16.7) 1 (4.8) NS
ART; n (%) 8 (66.7) 20 (95.2) .047
CD4+ count (min–max), cells/mL 551 (188–1313) 812 (438–1341) .01
VL (min–max), copies/mL 9500 (0–552,000) 342 (0–58,300) NS
Values are given as median (min–max) or otherwise stated.
ART= antiretroviral treatment, HIV = human immunodeficiency virus, RPR, rapid plasma regain, NS=nonsignificant, VL= viral load.
Pastuszczak et al. Medicine (2018) 97:45 Medicine
2
patients. Lumbar punctures were performed in all of these
patients. Based on the results of the CSF analysis, 5 cases (41.7%)
of asymptomatic neurosyphilis were identified. Three patients
had reactive CSF-VDRL. In the remaining 2, CSF-VDRL was
nonreactive, but they had both CSF white blood count (CSF-
WBC) of ≥20/mL and elevated CSF protein concentration (i.e.,
≥45mg/dL). The characteristics of individuals with and without
neurosyphilis are shown in Table 2.
Patients with neurosyphilis were characterized by significantly
higher RPR titer and higher viral load 12 months after syphilis
treatment when compared to those without neurosyphilis
(Table 2). Interestingly, all patients in whom neurosyphilis has
been excluded (no-neurosyphilis group) were on ART. In
contrast, only 1 patient from the neurosyphilis group (20%)
was receiving antiretroviral treatment (in this patient HIV RNA
levels and CD4+ count was 19,700copies/mL and 551cells/mL,
respectively).
The multivariate logistic regression analysis revealed that not
receiving ART independently increased the risk of neurosyphilis
among HIV-infected patients who remained serofast after
therapy of syphilis (R2=0.7, odds ratio=4.5; 95% confidence
interval 1.5–13.59, P= .003).
4. Discussion
Some previous studies evaluated the association of HIV status
with serologic outcomes after treatment of syphilis by comparing
patients with and without HIV infection.[9–12] However, results
of these studies are inconsistent, and it remains unclear whether
HIV-infected individuals are less likely to achieve a serologic
cure. These conflicting results can be explained, in part, by the
variability in the stages of syphilis and HIV infection status
among patients included in these studies, and by an inconsistent
definition of serologic nonresponse. More explicit seems to be
that patients co-infected with HIV may have a significantly
slower decrease in nontreponemal titer decrease than HIV-
uninfected individuals.
In the present study, 6 and 12 months after completing syphilis
therapy, 54.5% and 36.4% of patients (respectively) did not
achieve a serologic cure (i.e., at least 4-fold decrease in RPR titer
when compared to pretreatment values). When compared to
previous, similarly designed studies which were dedicated to the
assessment of serologic response among HIV-negative individu-
als, our findings seem to support the hypothesis of slower
serologic response and higher frequency of serofast state after
syphilis therapy in patients co-infected with HIV.[13–15]
In our study, the proportion of serologic responders
significantly increased at 12 months after therapy when
compared to this at 6 months (54.4% vs. 36.4%, respectively).
Such improvement of serologic treatment outcome has not been
observed among HIV-negative individuals with syphilis. Thus, it
may be reasonable to consider the diagnosis of serofast state in
patients with HIV not at 6 but at 12 months after completing the
treatment regimen.
To date, factors associated with serologic outcomes among
HIV-infected persons with syphilis have been analyzed only in a
limited number of studies. They found a CD4+ cell count of
<200cells/mL to be strongly correlated to serologic failure. It has
been also estimated that ART can reduce the risk of serofast
syphilis by more than 60%.[9] In the present study, we confirmed
these previous findings. However, due to a small sample size, it
was not possible to identify definite cut-off values for the CD4+
cells count that may be associated with higher risk of serologic
failure. Similar to previous results, we found that ART reduced
the risk of serofast state after treatment of syphilis by 65%.
Due to an inability to cultivate the causative agent of syphilis in
vitro, most testing for syphilis treatment outcome relies on
measurement of the immune responses. Untreated or inadequate-
ly treated syphilis can result in severe complications such as
neurosyphilis or cardiovascular syphilis. Not surprisingly,
considerable uncertainty exists as to whether the “serofast state”
indicates persistent infection of T pallidum or a residual immune
response in the absence of viable organisms. Only a few studies
have been performed to measure the response to therapy
following retreatment of serofast syphilis patients. They
demonstrated only a minimal improvement in serologic response
after retreatment with penicillin.[16,17] Therefore, it has been
suggested that serofast state may be only a sign of persistent
immune activation.
To the best of our knowledge, only 4 studies have performed
lumbar punctures among individuals with serologic nonresponse
to therapy of syphilis.[6–8,18] None of these studies were dedicated
to HIV-infected patients with syphilis. In our study, we found
high incidence of asymptomatic neurosyphilis (of 40%) among
serofast syphilis patients who were co-infected with HIV. It
should be highlighted that we used very strict criteria both for
serologic failure and neurosyphilis. Additionally, we showed a
significant association between the risk of neurosyphilis and
lower CD4+ cell count, higher viral load and not-receiving ART
at the posttreatment time point. In a multivariate analysis that
included all above-mentioned variables, we found not-receiving
ART to be independently associatedwith the risk of neurosyphilis
among HIV-infected individuals who remained serofast after
therapy of syphilis. Therefore, it seems that both CD4 cell
reconstitution and reducing of HIV in the blood can have additive
effect in the prevention of CNS involvement. On the other side,
even when patients who receive ART do not experience CD4 cell
increase, there are data to suggest that there are benefits to
Table 2
Characteristics of serofast state patients with and without neurosyphilis.
Neurosyphilis group (n=5) No-neurosyphilis group (n=7) P-value
Age (min–max), y 36 (29–53) 36 (26–54) NS
RPR 12 mo after therapy (min–max) 128 (32–512) 8 (4–16) .006
ART, n (%) 1 (20) 7 (100) .005
CD4+ count (min–max), cells/mL 332 (188–551) 628 (312–1313) .04
VL (min–max), copies/mL 94,950 (19,700–552,000) 204 (0–28,300) .01
CSF-WBC (min–max), cells/mL 32 (24–127) 6 (3–9) .003
CSF protein concentration (min–max), mg/dL 775 (429–1415) 547 (345–1098) NS
Values are given as median (min–max) or otherwise stated.
ART= antiretroviral treatment, NS=nonsignificant, RPR= rapid plasma regain, VL= viral load.
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outcome of syphilis treatment.[19] Thus, the impact of ART on the
response of HIV-infected patients with syphilis cannot be simply
explained by the CD4 cell reconstitution and reducing of viral
load.We can only speculate that ART can have pleiotropic effects
on the host immune response through mechanisms that have not
been explained yet.
A number of studies have found the natural course of syphilis
to be altered in HIV-infected patients.[20–22] Patients with HIV
infection have well-described dysfunction of antibody formation
what can result in less effective immune clearance of T
pallidum.[23] The findings of our study raise uncertainty as to
whether the serofast state in HIV-infected individuals is or is not
indicative of persistence of treponema since as many as 40% of
serofast patients had neurosyphilis. Further studies are needed to
investigate the clinical significance of the serofast state after
syphilis therapy among patients co-infected with HIV.
The small sample size and enrollment of patients only with
secondary and early latent syphilis reduces the generalizability of
our results. Despite an increasing number of cases worldwide,
syphilis remains a relatively rare disease in developed countries
(up to 3.5cases/100,000 per year in Poland). Thus, further multi-
center studies are needed.
In conclusion, we showed for the 1st time a high frequency of
asymptomatic neurosyphilis among HIV-infected individuals
who remain serofast after receiving the recommended therapy for
syphilis. Our results support the hypothesis that serologic failure
in this group can be, in a significant proportion of patients,
related to persistence of spirochetes. If left untreated, asymptom-
atic neurosyphilis may progress to the symptomatic phase and
result in severe neurologic and mental impairment. Thus, based
on these findings, we propose that CSF examination should be
considered in every HIV-infected patient who did not achieve
proper serologic response after syphilis therapy. Serofast patients
who are not receiving ART seem to be at particular risk of
neurosyphilis.
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